FDA Approves Erleada to Treat Non-Metastatic Prostate Cancer
First FDA-approved treatment for non-metastatic, castration-resistant prostate cancer
Disparities Seen in Gastric Cancer Patients’ Receipt of Pre-Op Chemo
Racial, ethnic disparities in treatment also affect disparities in overall survival
Education About Imaging Most Often Given by Ordering Provider
Delivery of pre-examination information to patients suboptimal; about half seek information themselves
USPSTF Recommends Against Ovarian Cancer Screening
Among asymptomatic women, harms of screening for ovarian cancer outweigh potential benefits
Four Best Practices Outlined to Prevent Health Care Cyberattacks
Health care execs should ID potential inefficiencies in cybersecurity, ensure systems backed up
Ultrasound for Rectal Cancer Staging Tied to More Chemoradiation
But no significant improvement in overall survival compared with CT of the abdomen and pelvis only
Criteria for Prostate Cancer Trials Disproportionately Exclude Blacks
Trials sponsored by academic investigators, cooperative groups more likely to use these criteria
Open-Label Placebo May Reduce Fatigue in Cancer Survivors
Reductions seen in fatigue symptom severity and fatigue-related quality of life disruption
EHRs Not Sufficient to Ensure Success in Value-Based Care
EHRs do not necessarily capture information needed; interoperability is poor, analytics are incomplete
Prognostic Model Developed for Immunotx of Urothelial Cancer
Model, based on six factors, predicts overall survival for patients treated with atezolizumab
